company background image
2IVA logo

Indivior DB:2IVA Stock Report

Last Price

€19.30

Market Cap

€2.8b

7D

0%

1Y

19.9%

Updated

13 Jun, 2023

Data

Company Financials +

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

2IVA Stock Overview

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally.

2IVA fundamental analysis
Snowflake Score
Valuation4/6
Future Growth4/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Indivior PLC Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Indivior
Historical stock prices
Current Share PriceUK£19.30
52 Week HighUK£78.00
52 Week LowUK£14.50
Beta-0.031
1 Month Change11.56%
3 Month Change24.52%
1 Year Change19.88%
3 Year Change297.12%
5 Year Change-9.81%
Change since IPO918.47%

Recent News & Updates

Recent updates

Shareholder Returns

2IVADE PharmaceuticalsDE Market
7D0%2.1%1.6%
1Y19.9%-26.3%6.4%

Return vs Industry: 2IVA exceeded the German Pharmaceuticals industry which returned -8.3% over the past year.

Return vs Market: 2IVA exceeded the German Market which returned 0.8% over the past year.

Price Volatility

Is 2IVA's price volatile compared to industry and market?
2IVA volatility
2IVA Average Weekly Movement8.7%
Pharmaceuticals Industry Average Movement6.3%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.2%
10% least volatile stocks in DE Market2.4%

Stable Share Price: 2IVA has not had significant price volatility in the past 3 months.

Volatility Over Time: 2IVA's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
20141,000Mark Crossleyhttps://www.indivior.com

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company’s product pipeline focuses on treating opioid use disorder, addiction, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet.

Indivior PLC Fundamentals Summary

How do Indivior's earnings and revenue compare to its market cap?
2IVA fundamental statistics
Market cap€2.80b
Earnings (TTM)-€46.46m
Revenue (TTM)€879.95m

3.2x

P/S Ratio

-60.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
2IVA income statement (TTM)
RevenueUS$947.00m
Cost of RevenueUS$161.00m
Gross ProfitUS$786.00m
Other ExpensesUS$836.00m
Earnings-US$50.00m

Last Reported Earnings

Mar 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.36
Gross Margin83.00%
Net Profit Margin-5.28%
Debt/Equity Ratio331.9%

How did 2IVA perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.